Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

Bayer’s consumer health business benefits from a narrow economic moat, largely because of its strong brand power. Consumers continue to pay a premium for Aspirin, Aleve, and other over-the-counter ...

Bayer’s strong first quarter performance was mainly driven by its pharmaceuticals division, even as its crop-science branch ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

Bayer said an adverse verdict in a US glyphosate lawsuit, which it is appealing against, had added to litigation costs. The company has also filed a petition with the US Supreme Court and has ...

Kiran Mazumdar-Shaw discusses the impact of US drug price reduction efforts on Indian pharma, Biocon's US expansion, strong ...

Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks ...

Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also ...

President Trump touted a new Executive Order that would more closely align drug prices in the US with those sold in Europe ...